Julia Carrasco-Zanini

Julia Carrasco-Zanini

Auto-generated profile, based on publicly available information

Julia Carrasco-Zanini

Precision Healthcare University Research Institute, Queen Mary University of London, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Science
Verified
Journal Article
Closed access
MPMaik Pietzner
Maik Pietzner
EWEleanor Wheeler
Eleanor Wheeler
JCJulia Carrasco-Zanini
Julia Carrasco-Zanini
ACAdrian Cortes
Adrian Cortes
MKMine Koprulu
Mine Koprulu
CLClaudia Langenberg
Claudia Langenberg
Detangling gene-disease connections: Many diseases are at least partially due to genetic causes that are not always understood or targetable with specific treatments. To provide insight into the biology of various human diseases as well as potential leads for therapeutic development, Pietzneret al. undertook detailed, genome-wide proteogenomic mapping. The authors analyzed thousands of connections between potential disease-associated mutations, specific proteins, and medical conditions, thereby providing a detailed map for use by future researchers. They also supplied some examples in which they applied their approach to medical contexts as varied as connective tissue disorders, gallstones, and COVID-19 infections, sometimes even identifying single genes that play roles in multiple clinical scenarios. —YN

22 July 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JCJulia Carrasco-Zanini
Julia Carrasco-Zanini
MPMaik Pietzner
Maik Pietzner
JDJonathan Davitte
Jonathan Davitte
PSPraveen Surendran
Praveen Surendran
DCDamien C. Croteau-Chonka
Damien C. Croteau-Chonka
CLClaudia Langenberg
Claudia Langenberg
For many diseases there are delays in diagnosis due to a lack of objective biomarkers for disease onset. Here, in 41,931 individuals from the United Kingdom Biobank Pharma Proteomics Project, we integrated measurements of ~3,000 plasma proteins with clinical information to derive sparse prediction models for the 10-year incidence of 218 common and rare diseases (81–6,038 cases). We then compared prediction models developed using proteomic data with models developed using either basic clinical information alone or clinical information combined with data from 37 clinical assays. The predictive performance of sparse models including as few as 5 to 20 proteins was superior to the performance of models developed using basic clinical information for 67 pathologically diverse diseases (median delta C-index = 0.07; range = 0.02–0.31). Sparse protein models further outperformed models developed using basic information combined with clinical assay data for 52 diseases, including multiple myeloma, non-Hodgkin lymphoma, motor neuron disease, pulmonary fibrosis and dilated cardiomyopathy. For multiple myeloma, single-cell RNA sequencing from bone marrow in newly diagnosed patients showed that four of the five predictor proteins were expressed specifically in plasma cells, consistent with the strong predictive power of these proteins. External replication of sparse protein models in the EPIC-Norfolk study showed good generalizability for prediction of the six diseases tested. These findings show that sparse plasma protein signatures, including both disease-specific proteins and protein predictors shared across several diseases, offer clinically useful prediction of common and rare diseases.

24 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MPMaik Pietzner
Maik Pietzner
EWEleanor Wheeler
Eleanor Wheeler
JCJulia Carrasco-Zanini
Julia Carrasco-Zanini
NKNicola D. Kerrison
Nicola D. Kerrison
EOErin Oerton
Erin Oerton
CLClaudia Langenberg
Claudia Langenberg
Affinity-based proteomics has enabled scalable quantification of thousands of protein targets in blood enhancing biomarker discovery, understanding of disease mechanisms, and genetic evaluation of drug targets in humans through protein quantitative trait loci (pQTLs). Here, we integrate two partly complementary techniques—the aptamer-based SomaScan® v4 assay and the antibody-based Olink assays—to systematically assess phenotypic consequences of hundreds of pQTLs discovered for 871 protein targets across both platforms. We create a genetically anchored cross-platform proteome-phenome network comprising 547 protein–phenotype connections, 36.3% of which were only seen with one of the two platforms suggesting that both techniques capture distinct aspects of protein biology. We further highlight discordance of genetically predicted effect directions between assays, such as for PILRA and Alzheimer’s disease. Our results showcase the synergistic nature of these technologies to better understand and identify disease mechanisms and provide a benchmark for future cross-platform discoveries.

23 February 2023 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
MKMine Koprulu
Mine Koprulu
JCJulia Carrasco-Zanini
Julia Carrasco-Zanini
EWEleanor Wheeler
Eleanor Wheeler
SLSam Lockhart
Sam Lockhart
NKNicola D. Kerrison
Nicola D. Kerrison
CLClaudia Langenberg
Claudia Langenberg
Studying the plasma proteome as the intermediate layer between the genome and the phenome has the potential to identify new disease processes. Here, we conducted a cis-focused proteogenomic analysis of 2,923 plasma proteins measured in 1,180 individuals using antibody-based assays. We (1) identify 256 unreported protein quantitative trait loci (pQTL); (2) demonstrate shared genetic regulation of 224 cis-pQTLs with 575 specific health outcomes, revealing examples for notable metabolic diseases (such as gastrin-releasing peptide as a potential therapeutic target for type 2 diabetes); (3) improve causal gene assignment at 40% (n = 192) of overlapping risk loci; and (4) observe convergence of phenotypic consequences of cis-pQTLs and rare loss-of-function gene burden for 12 proteins, such as TIMD4 for lipoprotein metabolism. Our findings demonstrate the value of integrating complementary proteomic technologies with genomics even at moderate scale to identify new mediators of metabolic diseases with the potential for therapeutic interventions.

10 November 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JCJulia Carrasco-Zanini
Julia Carrasco-Zanini
MPMaik Pietzner
Maik Pietzner
JLJoni V. Lindbohm
Joni V. Lindbohm
EWEleanor Wheeler
Eleanor Wheeler
EOErin Oerton
Erin Oerton
CLClaudia Langenberg
Claudia Langenberg

24 January 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SYSatoshi Yoshiji
Satoshi Yoshiji
TLTianyuan Lu
Tianyuan Lu
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
JCJulia Carrasco-Zanini-Sanchez
Julia Carrasco-Zanini-Sanchez
CSChen-Yang Su
Chen-Yang Su
JRJ. Brent Richards
J. Brent Richards
Obesity strongly increases the risk of cardiometabolic diseases, yet the underlying mediators of this relationship are not fully understood. Given that obesity strongly influences circulating protein levels, we investigated proteins mediating the effects of obesity on coronary artery disease, stroke and type 2 diabetes. By integrating two-step proteome-wide Mendelian randomization, colocalization, epigenomics and single-cell RNA sequencing, we identified five mediators and prioritized collagen type VI α3 (COL6A3). COL6A3 levels were strongly increased by body mass index and increased coronary artery disease risk. Notably, the carboxyl terminus product of COL6A3, endotrophin, drove this effect. COL6A3 was highly expressed in disease-relevant cell types and tissues. Finally, we found that body fat reduction could reduce plasma levels of COL6A3-derived endotrophin, indicating a tractable way to modify endotrophin levels. In summary, we provide actionable insights into how circulating proteins mediate the effects of obesity on cardiometabolic diseases and prioritize endotrophin as a potential therapeutic target.